We’re

/vairˈoo/

Veru Inc. is an Oncology and Urology Biopharmaceutical Company Developing and Commercializing Novel Medicines for Prostate Cancer and Urology Specialty Pharmaceuticals.

PHARMACEUTICALS

VERU-111 Prostate Cancer

VERU-111 Prostate Cancer

A novel oral selective antitubulin that targets alpha and beta tubulin for metastatic prostate cancer as well as for other forms of advanced cancers.

LEARN MORE

VERU-111 COVID-19

VERU-111 COVID-19

Novel Microtubule Depolymerization Drug with Dual Mechanism of Action – Antiviral for SARS-COV-2 & Anti-Inflammatory for Cytokine Storm

LEARN MORE

VERU-100 Prostate Cancer

VERU-100 Prostate Cancer

VERU-100 is a novel, proprietary peptide formulation designed with multiple beneficial clinical attributes addressing the shortfalls of the current multi-billion-dollar androgen deprivation therapy market for advanced prostate cancer.

LEARN MORE

Zuclomiphene citrate

Zuclomiphene citrate

Estrogen receptor agonist for the treatment of hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer.

LEARN MORE

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

TADFIN® combination of a PDE5 inhibitor and 5 alpha reductase inhibitor for the treatment of enlarged prostate (BPH)

LEARN MORE

LATEST NEWS

Jefferies 2020 Healthcare Conference

June 2, 2020

Watch the replay of our presentation at the Jefferies 2020 Healthcare Conference on June 2, 2020

Watch the Replay
MORE NEWS